K. Martijn Akkerhuis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
K. Martijn Akkerhuis has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
E Boersma
Erasmus Medical Center, Rotterdam, Netherlands
3 shared publications- Folkert W. Asselbergs
Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
3 shared publications I Kardys
Erasmus Medical Center, Rotterdam, Netherlands
3 shared publicationsA. Michael Lincoff
From Thoraxcenter (K.M.A., E.B., M.L.S.), University Hospital Rotterdam, The Netherlands; Duke University Medical Center (J.H.A., B.E.T., R.A.H.), Durham, NC; and Cleveland Clinic Foundation (A.M.L.), Cleveland, Ohio
2 shared publicationsE. Boersma
Erasmus Medical Center, Department of Cardiology, Rotterdam, Netherlands
2 shared publicationsEric Boersma
From Thoraxcenter (K.M.A., E.B., M.L.S.), University Hospital Rotterdam, The Netherlands; Duke University Medical Center (J.H.A., B.E.T., R.A.H.), Durham, NC; and Cleveland Clinic Foundation (A.M.L.), Cleveland, Ohio
2 shared publications
Latest Publications
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P5665Coagulation biomarkers and clinical outcomes in patients with chronic heart failure - The bio-shift study
Background: Chronic heart failure (CHF) is a well-known risk factor for thrombotic events, but the predictive value of biomarkers of coagulation in these patients are unknown. We studied 6 biomarkers within the coagulation cascade, and investigated whether their upregulation during the course of CHF is associated with adverse clinical events.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P5665Coagulation biomarkers and clinical outcomes in patients with chronic heart failure - The bio-shift study
Background: Chronic heart failure (CHF) is a well-known risk factor for thrombotic events, but the predictive value of biomarkers of coagulation in these patients are unknown. We studied 6 biomarkers within the coagulation cascade, and investigated whether their upregulation during the course of CHF is associated with adverse clinical events.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P1558The time course of immuno- and inflammo-proteomics prior to a recurrent coronary event in post-acute coronary syndrome patients
Background and purpose: More insights on the role of the immune and inflammatory system in atherosclerosis are required to better understand their share in the pathophysiology of cardiovascular disease (CVD). Therefore, we assessed the time course of immuno- and inflammo-proteomics prior to the development of a recurrent acute coronary syndrome (reACS), in post-ACS patients.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P1558The time course of immuno- and inflammo-proteomics prior to a recurrent coronary event in post-acute coronary syndrome patients
Background and purpose: More insights on the role of the immune and inflammatory system in atherosclerosis are required to better understand their share in the pathophysiology of cardiovascular disease (CVD). Therefore, we assessed the time course of immuno- and inflammo-proteomics prior to the development of a recurrent acute coronary syndrome (reACS), in post-ACS patients.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P6245High frequency metabolite profiling and the incidence of recurrent coronary events in post-acute coronary syndrome patients
Background and purpose: Precision medicine is currently shifting to metabolomic research, to identify new biomarkers of cardiovascular disease. We studied changes in metabolite profiles prior to the development of an acute coronary syndrome (ACS).
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P6245High frequency metabolite profiling and the incidence of recurrent coronary events in post-acute coronary syndrome patients
Background and purpose: Precision medicine is currently shifting to metabolomic research, to identify new biomarkers of cardiovascular disease. We studied changes in metabolite profiles prior to the development of an acute coronary syndrome (ACS).
- 1 August 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (suppl_1)
P3653Evolution of renal function after acute coronary syndrome and prognostic impact of serial renal assessments in patients with normal-to-moderately reduced glomerular filtration rates: BIOMArCS study
Background: Despite the prognostic importance of renal dysfunction in acute coronary syndrome (ACS), its temporal evolution following ACS has not been investigated in detail.
- 1 August 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (suppl_1)
P3653Evolution of renal function after acute coronary syndrome and prognostic impact of serial renal assessments in patients with normal-to-moderately reduced glomerular filtration rates: BIOMArCS study
Background: Despite the prognostic importance of renal dysfunction in acute coronary syndrome (ACS), its temporal evolution following ACS has not been investigated in detail.
- 5 February 2002
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (5) , 554-556
Minor Myocardial Damage and Prognosis
Background — The relevance of the adverse prognostic implications of CK-MB elevation after percutaneous coronary intervention (PCI) remains controversial. Therefore, we compared the relationship between the level of postprocedural CK-MB elevation and 6-month mortality in patients undergoing PCI with the relationship between the level of spontaneous, non–PCI-related CK-MB elevation and 6-month mortality in patients with acute coronary syndromes (ACS) treated medically. Methods and Results — In the PURSUIT trial, 5583 of 9461 patients who presented with a non–ST-elevation ACS did not undergo PCI or CABG and had at least 1 CK-MB sample collected during index-hospitalization. There was a gradual increase in 6-month mortality with higher CK-MB levels: 4.1%, 8.6%, 9.0%, 14.3%, 15.5% for CK-MB ratios 0 to 1, >1 to 3, >3 to 5, >5 to 10, and >10 times the upper limit of normal. A combined analysis in 8838 patients undergoing PCI in 5 large, clinical trials revealed a proportional relationship between postprocedural CK-MB levels (≤48 hours after PCI) and 6-month mortality. In patients with CK-MB ratios 0 to 1, >1 to 3, >3 to 5, >5 to 10, and >10, the risk of death was 1.3%, 2.0%, 2.3%, 4.3%, and 7.4%, respectively. The absolute mortality rates were lower after procedure-related infarcts compared with spontaneous infarcts. Yet, the relative increase in 6-month mortality with each increase in peak CK-MB level was similar for PCI-related myocardial necrosis and spontaneous myocardial necrosis, as all tests for heterogeneity of the odds ratios were nonsignificant. Conclusions — The present analysis indicates that the adverse prognostic implications of periprocedural myocardial necrosis should be considered similar to the adverse consequences of spontaneous myocardial necrosis.
- 5 February 2002
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (5) , 554-556
Minor Myocardial Damage and Prognosis
Background — The relevance of the adverse prognostic implications of CK-MB elevation after percutaneous coronary intervention (PCI) remains controversial. Therefore, we compared the relationship between the level of postprocedural CK-MB elevation and 6-month mortality in patients undergoing PCI with the relationship between the level of spontaneous, non–PCI-related CK-MB elevation and 6-month mortality in patients with acute coronary syndromes (ACS) treated medically. Methods and Results — In the PURSUIT trial, 5583 of 9461 patients who presented with a non–ST-elevation ACS did not undergo PCI or CABG and had at least 1 CK-MB sample collected during index-hospitalization. There was a gradual increase in 6-month mortality with higher CK-MB levels: 4.1%, 8.6%, 9.0%, 14.3%, 15.5% for CK-MB ratios 0 to 1, >1 to 3, >3 to 5, >5 to 10, and >10 times the upper limit of normal. A combined analysis in 8838 patients undergoing PCI in 5 large, clinical trials revealed a proportional relationship between postprocedural CK-MB levels (≤48 hours after PCI) and 6-month mortality. In patients with CK-MB ratios 0 to 1, >1 to 3, >3 to 5, >5 to 10, and >10, the risk of death was 1.3%, 2.0%, 2.3%, 4.3%, and 7.4%, respectively. The absolute mortality rates were lower after procedure-related infarcts compared with spontaneous infarcts. Yet, the relative increase in 6-month mortality with each increase in peak CK-MB level was similar for PCI-related myocardial necrosis and spontaneous myocardial necrosis, as all tests for heterogeneity of the odds ratios were nonsignificant. Conclusions — The present analysis indicates that the adverse prognostic implications of periprocedural myocardial necrosis should be considered similar to the adverse consequences of spontaneous myocardial necrosis.
- Open Access
- 4 July 2001
- Published by American Medical Association (AMA) in JAMA
- Vol. 286 (1) , 78-82
Risk of Stroke Associated With Abciximab Among Patients Undergoing Percutaneous Coronary Intervention
Intravenous platelet glycoprotein (GP) IIb/IIIa receptor inhibitors effectively reduce thrombotic complications in patients undergoing percutaneous coronary intervention (PCI).1-6 In randomized studies, treatment with abciximab (a monoclonal antibody Fab fragment directed against the platelet GP IIb/IIIa receptor7) resulted in an approximate 50% reduction in the composite of death or myocardial infarction at 30 days.1-4 However, inhibition of platelet aggregation by GP IIb/IIIa receptor blockers such as abciximab increases the risk of bleeding complications, particularly when these agents are combined with conventional doses of heparin.1-8
- 4 July 2001
- Published by American Medical Association (AMA) in JAMA
- Vol. 286 (1) , 78-82
Open AccessRisk of Stroke Associated With Abciximab Among Patients Undergoing Percutaneous Coronary Intervention
Intravenous platelet glycoprotein (GP) IIb/IIIa receptor inhibitors effectively reduce thrombotic complications in patients undergoing percutaneous coronary intervention (PCI).1-6 In randomized studies, treatment with abciximab (a monoclonal antibody Fab fragment directed against the platelet GP IIb/IIIa receptor7) resulted in an approximate 50% reduction in the composite of death or myocardial infarction at 30 days.1-4 However, inhibition of platelet aggregation by GP IIb/IIIa receptor blockers such as abciximab increases the risk of bleeding complications, particularly when these agents are combined with conventional doses of heparin.1-8